- Home
- NTZ vs ANTX Comparison
NTZ vs ANTX Comparison
Compare NTZ & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTZ
- ANTX
- Stock Information
- Founded
- NTZ 1959
- ANTX 2017
- Country
- NTZ Italy
- ANTX United States
- Employees
- NTZ N/A
- ANTX N/A
- Industry
- NTZ Home Furnishings
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- NTZ Consumer Discretionary
- ANTX Health Care
- Exchange
- NTZ Nasdaq
- ANTX Nasdaq
- Market Cap
- NTZ 45.4M
- ANTX 40.0M
- IPO Year
- NTZ 1993
- ANTX 2022
- Fundamental
- Price
- NTZ $4.15
- ANTX $1.32
- Analyst Decision
- NTZ
- ANTX Hold
- Analyst Count
- NTZ 0
- ANTX 5
- Target Price
- NTZ N/A
- ANTX $3.50
- AVG Volume (30 Days)
- NTZ 3.4K
- ANTX 833.6K
- Earning Date
- NTZ 12-12-2024
- ANTX 11-13-2024
- Dividend Yield
- NTZ N/A
- ANTX N/A
- EPS Growth
- NTZ N/A
- ANTX N/A
- EPS
- NTZ N/A
- ANTX N/A
- Revenue
- NTZ $365,846,531.00
- ANTX N/A
- Revenue This Year
- NTZ N/A
- ANTX N/A
- Revenue Next Year
- NTZ N/A
- ANTX N/A
- P/E Ratio
- NTZ N/A
- ANTX N/A
- Revenue Growth
- NTZ N/A
- ANTX N/A
- 52 Week Low
- NTZ $3.80
- ANTX $0.87
- 52 Week High
- NTZ $7.20
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- NTZ 40.50
- ANTX 50.02
- Support Level
- NTZ $3.85
- ANTX $1.32
- Resistance Level
- NTZ $4.45
- ANTX $1.59
- Average True Range (ATR)
- NTZ 0.23
- ANTX 0.09
- MACD
- NTZ -0.08
- ANTX -0.03
- Stochastic Oscillator
- NTZ 18.18
- ANTX 7.89
About NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio including sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of revenue from the United States of America and also has an international presence in Italy, Spain, UK and Other countries.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.